# US 2016/0355567 A1 · Multimeric il-15 soluble fusion molecules and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355567 A1
- Document ID: US20160355567A1
- Status: Published application
- Kind: A1
- Application number: 15/213,991
- Filed: 2016-07-19
- Published: 2016-12-08
- Earliest claimed: 2010-09-21
- Assignees: Altor BioScience Corporation
- Applicants: Altor Bioscience Corporation
- Inventors: Hing C. Wong; Peter Rhode; Bai Liu; Xiaoyun Zhu; Kai-ping Han
- Web page: https://patentgrep.com/patent/US20160355567A1

## CPC

- C07K 14/7155: {for interleukins [IL]}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5443: {IL-15}
- C07K 16/18: against material from animals or humans
- C07K 16/2887: {against CD20}
- C12N 15/09: Recombinant DNA-technology
- C12N 15/62: DNA sequences coding for fusion proteins
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15Rα) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15Rα domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

## Claims

### Claim 1

A soluble fusion protein complex comprising at least two soluble fusion proteins, wherein
the first fusion protein comprises (a) a first biologically active polypeptide covalently linked to (b) interleukin-15 (IL-15) polypeptide or a functional fragment thereof; and
the second fusion protein comprises (c) a second biologically active polypeptide covalently linked to (d) soluble interleukin-15 receptor alpha (IL-15Rα) polypeptide or a functional fragment thereof
wherein one or both of the first and second fusion proteins further comprise an immunoglobulin Fc domain or a functional fragment thereof;
wherein IL-15 domain of the first fusion protein binds to the soluble IL-15Rα domain of the second fusion protein to form a soluble fusion protein complex.

### Claim at position 2

-41. (canceled)

### Claim 42 (depends on 1)

A nucleic acid sequence encoding the first fusion protein of claim 1.

### Claim 43 (depends on 1)

A nucleic acid sequence encoding the second fusion protein of claim 1.

### Claim 44

(canceled)

### Claim 45 (depends on 42)

A DNA vector comprising the nucleic acid sequence of claim 42.

### Claim 46 (depends on 43)

A DNA vector comprising the nucleic acid sequence of claim 43.

### Claim at position 8

-54. (canceled)

### Claim 55 (depends on 1)

A method for killing a target cell, the method comprising:
a) contacting a plurality of cells with a soluble fusion protein complex of claim 1, wherein the plurality of cells further comprises immune cells bearing the IL-15R chains recognized by the IL-15 domain of claim 1 or immune cells bearing Fc receptor chains recognized by the Fc domain of claim 1 and the target cells bearing an antigen recognized by at least one of the biologically active polypeptides of claim 1,
b) forming a specific binding complex (bridge) between the antigen on the target cells and the IL-15R or Fc receptor chains on the immune cells sufficient to bind and activate the immune cells; and
c) killing the target cells by the bound activated immune cells.

### Claim at position 10

-59. (canceled)

### Claim 60 (depends on 1)

A method for preventing or treating disease in a patient in which the diseased cells express a disease associated antigen, the method comprising:
a) administering to the patient a soluble fusion protein complex of claim 1 comprising a biologically active polypeptide recognizing a disease-associated antigen;
b) forming a specific binding complex (bridge) between antigen-expressing diseased cells and IL-15R or Fc receptor expressing immune cells sufficient to localize the immune cells; and
c) damaging or killing the disease cells sufficient to prevent or treat the disease in the patient.

### Claim 61 (depends on 1)

A method for preventing or treating disease in a patient in which the diseased cells express a disease associated antigen, the method comprising:
a) mixing immune cells bearing IL-15R chains or Fc receptor chains with a soluble fusion protein complex of claim 1 comprising a biologically active polypeptide recognizing a disease-associated antigen,
b) administering to the patient the immune cell-fusion protein complex mixture;
c) forming a specific binding complex (bridge) between antigen-expressing diseased cells and IL-15R or Fc receptor expressing immune cells sufficient to localize the immune cells; and
d) damaging or killing the disease cells sufficient to prevent or treat the disease in the patient.

### Claim at position 13

-63. (canceled)

### Claim 64 (depends on 1)

A method of stimulating immune responses in a mammal comprising administering to the mammal an effective amount of the soluble fusion protein complex of claim 1.

### Claim 65 (depends on 1)

A method of suppressing immune responses in a mammal comprising administering to the mammal an effective amount of the soluble fusion protein complex of claim 1.

### Claim at position 16

-74. (canceled)

### Claim 75

A method for making an interleukin-15 (IL-15):interleukin-15 receptor alpha (IL-15Rα) fusion protein complex, the method comprising:
a) introducing into a host cell a first DNA vector encoding IL-15 and a second DNA vector encoding an IL-15Rα fusion protein;
b) culturing the host cell in media under conditions sufficient to express the IL-15 and the IL-15Rα fusion protein; and
c) purifying the IL-15:IL-15Rα fusion protein complex from the host cell or media.

### Claim at position 18

-94. (canceled)

### Claim 95

A method of making an IL-15N72D:IL-15RαSu/Fc fusion protein complex comprising:
a) co-expressing IL-15N72D and an IL-15RαSu/Fc fusion protein in a host cell;
b) culturing the host cell in media under conditions sufficient to express the IL-15N72D and the IL-15RαSu/Fc fusion protein; and
c) purifying the IL-15N72D:IL-15RαSu/Fc fusion protein complex from the host cell or media wherein both IL-15 binding sites of the IL-15N72D:IL-15RαSu/Fc complex are fully occupied.

### Claim at position 20

-104. (canceled)

### Claim 105 (depends on 95)

An isolated fully occupied IL-15N72D:IL-15RαSu/Fc complex produced according to the method of claim 95.

### Claim 106 (depends on 105)

A method of modulating an immune response in a subject, the method comprising administering to the subject the fully occupied IL-15N72D:IL-15RαSu/Fc complex of claim 105.

### Claim 107

(canceled)

### Claim 108 (depends on 105)

A method of enhancing an immune response in a subject having neoplasia, the method comprising administering to the subject the fully occupied il-15n72d:i1-15rαsu/fc complex of claim 105.
